Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Immune cells engineered to fight lupus enter first human tests

NCT ID NCT07358988

First seen Jan 24, 2026 · Last updated Jun 16, 2026 · Updated 15 times

Summary

This early-stage trial tests a new treatment called KN5501 for people with moderate to severe lupus that hasn't responded to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) to target and destroy faulty B cells that drive the disease. Participants will receive one or more infusions after a short chemotherapy-like prep, and researchers will monitor safety, side effects, and whether lupus activity decreases.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERTHEMATOSUS (SLE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bengbu Medical College First Affiliated Hospital

    Bengbu, Anhui, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Changhai Hospital of Shanghai

    Shanghai, Shanghai Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.